| Title | Organization | Keywords | LOI Due Date | Application Due Date |
|---|---|---|---|---|
| (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments | National Cancer Institute | prevention, control | 1/8/2028 | |
| (NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research | National Cancer Institute | biomarkers, lifestyle interventions, prevention, interception, diet, physical activity | 1/8/2027 | |
| (NOSI): Analysis of Existing Linked Datasets to Understand the Relationship between Housing Program Participation and Risk for Chronic Diseases and Other Conditions (R01-Clinical Trial Not Allowed) | National Institutes of Health | health disparities | 9/8/2027 | |
| (NOSI): Mechanisms Driving Obesity and Prostate Cancer Risk | National Cancer Institute | prostate, risk, prevention | 1/8/2028 | |
| National Cancer Institute | Health disparities | 6/18/0275 | ||
| NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed) | National Institutes of Health | infrastructure, consortium support, data resources, community tools, resource dissemination | 6/15/2026 | |
| Leukemia Exploration and Prevention Grant Program (LEAP) | American Cancer Society (ACS) | OAFS, innovation, early stage | 6/1/2026 | |
| Partnering Research and Community Organizations for Comparative Clinical Effectiveness Research Across the Cancer Care Continuum - Cycle 1 2026 | Patient-Centered Outcomes Research Institute (PCORI) | OAFS, community, engagement, population | 1/6/2026 | 5/5/2026 |
| John Voight Memorial Leukemia Research Grant | Kids Beating Cancer | OAFS, pediatric, hematology, blood, malignancies, treatment resistance, relapse prevention, therapeutic, innovation | 7/3/2026 | 10/16/2026 |
| ACCESS Award | Rising Tide Foundation | OAFS, global health, implementation, healthcare, community | 3/9/2026 | 4/30/2026 |
| The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional) | National Cancer Institute | career development, prevention, population, clinical trial, mentorship, community | 6/18/2026 | |
| Collaborative Research Development Grant | Ovarian Cancer Research Alliance | OAFS, Interdisciplinary collaborations, screening and early detection, etiology and prevention, molecular therapeutics, cancer biology and genetics | 3/25/2026 | 6/10/2026 |
| Collaborative Research Development Grant – Microsoft AI for Health | Ovarian Cancer Research Alliance | OAFS, Interdisciplinary collaborations, screening and early detection, etiology and prevention, molecular therapeutics, cancer biology and genetics, AI, Artificial Intelligence | 3/25/2026 | 6/10/2026 |
| Sickle Cell Advocacy & Leadership Empowerment (SCALE) Grants | Pfizer | OAFS, leadership development, community engagement, patient, outreach | 5/13/2026 | |
| NCI Pathway to Independence Award for Early - Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required) | National Cancer Institute | Limited, early-stage, postdoctoral, cancer control, cancer prevention, data science | 6/15/2026 | |
| NCI Pathway to Independence Award for Early - Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) | National Cancer Institute | Limited, early-stage, postdoctoral, cancer control, cancer prevention, data science | 6/15/2026 | |
| Yosemite-American Cancer Society Award | American Cancer Society (ACS) | OAFS, prevention, treatment, DNA, mRNA, tumor, biology, deetection, treatment, therapeutic, biomarkers | 6/24/2026 | |
| Cancer Health Research Centers (CHERCs) | American Cancer Society (ACS) | OAFS, population, community, engagement, multidisciplinary | 6/1/2026 | |
| Biology to Prevention Award (CRUK) | American Cancer Society (ACS) | OAFS, risk reduction, carcinogenesis, molecular pathways, early detection, prevention, biomarkers, intervention, biology | 6/11/2026 | 6/18/2026 |
| Developing Educational Initiatives for Implementation and Therapy Management of B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM) | Pfizer | OAFS, therapy, initiatives, myeloma, clinical, training, treatment, community, hematologic, patient care, multidisciplinary | 5/18/2026 |
